DOI: 10.5281/zenodo.21937348

View latest PathMap Research

DISCLAIMER: This data is not peer reviewed and is NOT professional advice.
Original Text Evaluated

Discovery: Considering PubMed #37563705, #42012729, and #42541426, Spermidine is a known inducer of autophagy through EP300 inhibition and TFEB activation. Since TMEM106B amylofilaments induce lysosomal dysfunction, TFEB-driven restoration of lysosomal capacity would logically prevent the accumulation of these filaments.

Plausibility Verdicts

Evaluation 1

Yes, spermidine-induced TFEB activation is a proven mechanism for enhancing lysosomal function. While TMEM106B amyloid accumulation is associated with lysosomal dysfunction, the direct clearance of these specific filaments by spermidine-mediated TFEB activation has not been definitively demonstrated.

Dataset Summary

Novel & Overlooked Insights

  • Spermidine supplementation acts as a downstream effector of the anti-aging effects induced by fasting and rapamycin.
  • TMEM106B amyloid filaments demonstrate age-dependent formation in astrocytes and reside in endosomal/lysosomal compartments.
  • TFEB phase separation is essential for its transcriptional activation and anti-inflammatory functions induced by nutrient stress.
  • The TFEB-ATP6V0C axis is a critical determinant of microglial proteostasis and alpha-synuclein clearance.
  • TMEM106B single nucleotide polymorphisms are associated with cognitive resilience in Alzheimer's disease cases, independent of amyloid plaque burden.
  • Spermidine-induced autophagy via TFEB can rescue mitochondrial function in several cell types, including Sertoli cells and cardiomyocytes.
  • The induction of ER-phagy via FAM134B is transcriptionally regulated by TFEB/TFE3, creating a secondary layer of proteostasis regulation.

Extracted Discoveries

Suggested Experiments
  • Determine if spermidine or TFEB overexpression accelerates the degradation rate of TMEM106B filaments in primary neuronal culture models.
  • Assess whether TFEB knockdown increases TMEM106B amyloid burden in microglia during aging-induced stress.
Suggested Studies
  • Longitudinal analysis of CSF TMEM106B levels in individuals undergoing long-term spermidine supplementation.
  • Comparative proteomics of lysosomal contents in patients with high vs. low TMEM106B aggregate burden treated with autophagy-inducing agents.
Swansons Literature Based Discovery Candidates
  • Spermidine-mediated TFEB activation may modulate the biophysical properties of the Biondi body variant of TMEM106B filaments to reduce amyloid burden.
  • Spermidine/TFEB axis (Source #42588134, #42012729)
  • TMEM106B amyloid filaments in Biondi bodies (Source #39503754, #38886865)
  • Lysosomal degradative capacity and acidification (Source #42546981)
  • TFEB is the master regulator of lysosomal biogenesis; since Biondi bodies are amyloid inclusions found within secondary lysosomes, enhancing lysosomal degradative capacity via TFEB activation provides a logical mechanism to influence their clearance.
Contradictions Between Evidences
  • None identified in the provided text, though the 'double-edged' role of autophagy in tumor survival vs. suppression is noted.
Repurposed Solutions
  • The use of TFEB activators, such as spermidine or the curcumin analog CM-C1, serves as a multipurpose strategy to restore autophagic flux in conditions ranging from neurodegeneration to inflammatory bowel disease.
Support open science: Order your own dataset here.

PathMap is funded by sales of datasets and coversheets to researchers of any kind who wish to discover the most viable routes and paths to accelerate cures. We do not make theoretical molecules, we expose the truth in current PubMed literature. Commission a trace today.

Investigator Profile

👨‍🔬
Joshua Dungan
PathMap Admin
PathMap PathMap Image